Richard Finn, MD

Articles

Dr. Finn on Treatment Considerations for HCC

March 16th 2021

Richard S. Finn, MD, discusses treatment considerations for patients with hepatocellular carcinoma.

Dr. Finn on Considerations for Lenvatinib in Liver Cancer

September 19th 2018

Richard Finn, MD, associate professor of medicine, University of California, Los Angeles David Geffen School of Medicine, discusses the role of lenvatinib in the treatment of patients with liver cancer.

Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm

September 16th 2018

Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.

Dr. Finn on Significance of Phase III Findings of Lenvatinib in HCC

September 16th 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Dr. Finn on Current and Emerging Agents in the Field of HCC

September 16th 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

Dr. Finn on Results of RESOURCE Study in Liver Cancer

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses results of the RESOURCE study in advanced liver cancer.

Dr. Finn on Studies of Pembrolizumab for Hepatocellular Carcinoma

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses studies of pembrolizumab (Keytruda) in patients with previously untreated hepatocellular carcinoma (HCC).

Dr. Finn on the Promise of Regorafenib for the Treatment of HCC

January 21st 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial.

Dr. Richard Finn on What's Next for Palbociclib After PALOMA in Breast Cancer

November 11th 2016

Richard Finn, MD associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses what’s next for palbociclib following the PALOMA trials.